Special Issue: Advancements in Osteosarcoma

Special Issue:

Advancements in Osteosarcoma

Osteosarcoma is the most frequent pediatric primary bone tumor. While current treatments that combine conventional chemotherapies and surgery have reached a five-year remission rate higher than 70%, this rate dramatically decreases below 30% if metastases are observed at the time of diagnosis or if the tumor is resistant to chemotherapy. Research on new therapeutic targets to eradicate tumor cells (such as epigenetic, genetic, and metabolic targets) are critical to developing our understanding of the disease.

This Special Issue will focus on recent developments in our understanding of Osteosarcoma and possible paths towards new treatment options.

Effects of Cabozantinib on Human G292 Osteosarcoma Cells

Longjie Chen, Dinh Nguyen, Ryan Kaminsky, Jennifer Helfer, Rosemary Dziak, Ph.D.

Management of chest wall tumors: 15 years clinical experience, a retrospective study of 52 patients

Vinicius Basso Preti, Gerardgo C.G. Valladaress, Tariane F. Foiato, Jessica Takaki

Phloridzin docosahexaenoate, a novel polyphenolic derivative, is cytotoxic to canine osteosarcoma D17 cells

Beth Murray, Niroshaa Arumuggam, Tess Astatkie, H.P. Vasantha Rupasinghe

Osteosarcoma: A review with emphasis on pathogenesis and chemoresistance

Steven J. Kuerbitz, MD, Matthew B. Henderson, DO